Pregnancy after cancer: when impossible becomes possible

Authors

  • Ю. А. Тимовская National Medical University named after A.A. Bogomolets, Ukraine

DOI:

https://doi.org/10.18370/2309-4117.2015.21.82-88

Keywords:

survival after cancer, pregnancy after cancer, fertility preservation, ovary pexia, ovarian suppression, embryo cryopreservation, oocyte cryopreservation, Progestogel, Utrogestan

Abstract

The article is a summary of the report «Save of reproductive function in cancer patients» which was presented at the conference «Oncopathology and Reproduction - Opportunities and Prospects», that was held in October 29, 2014 in Kiev.

Today the improvement of radiation therapy and the development of new cytotoxic drugs improved both immediate and long-term results of cancer patients’ treatment.

Recommendations of the American Society of Clinical Oncology provide discussion about saving of reproductive function with every cancer patients of reproductive age before initiating therapy. This decision should be taken in conjunction patient, an oncologist and reproductive system.

All methods of fertility preservation are divided into two groups: methods to reduce the risk of ovarian tissue damage by radiation therapy and chemotherapy (ovary pexia and ovarian suppression); methods aimed at saving biological material (embryo cryopreservation and cryopreservation of oocytes).

It should be noted that all cancer patients need to understand the high risk of disease prolongation or complications from the use of such treatments.

Author Biography

Ю. А. Тимовская, National Medical University named after A.A. Bogomolets

PhD, assistant of the Oncology Department

References

  1. Howlader, C.N., Krapcho, M., Neyman, N., et al. SEER Cancer Statistic Review, 1975-2009. National cancer Institute (2012). [http://www.seer.cancer.gov/].
  2. E thic Committee American Society for Reproductive Medicine. “Fertility preservation and reproduction in patients facing gonadotoxic therapies: a committee opinion.” Fertil Steril, 5(100) (2013): 1223-1230.
  3. A merican Society of Clinical Oncology. Practice Guidelines [http://www.instituteforquality.org/practice-guidelines] Last accessed March 4, 2015.
  4. D onnez, J., Martinez-Madrid, B., Jadoul, P., van Langendoncket, A., Demylle, D., Dolmans, M.M. “Ovarian tissue cryopreservation and transplantation: a review.” Hum Reprod Update, 12(2006): 519-535.
  5. Barrat, J., at all. “The in vivo effect of the local administration of progesterone on the mitotic activity of human ductal breast tissue. Results of a pilot study.” J Gynecol Obstet Biol Reprod (Paris), 19(3) (1990): 269–274.
  6. Schroeder, W. “Lokale Hormon-Therapie hilft meistens.” Arztliche Praxis, 89(1984): 2616 - 2619.
  7. “Luteal-phase support in assisted reproduction treatment: real-life practices reported worldwide by anupdated website-based survey.” Reprod Biomed Online, 28(3) (2014): 330-335.

Downloads

Published

2015-02-11

How to Cite

Тимовская, Ю. А. (2015). Pregnancy after cancer: when impossible becomes possible. REPRODUCTIVE ENDOCRINOLOGY, (21), 82–88. https://doi.org/10.18370/2309-4117.2015.21.82-88

Issue

No. 21 (2015)

Section

Events

License

Copyright (c) 2015 Ю. А. Тимовская

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

Authors who publish with this journal agree to the following terms:

    1. Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.

    1. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.